Essential Tremor: A Neurodegenerative Disease?

Julián Benito-León 1,2,3*

1 Department of Neurology, University Hospital “12 de Octubre”, Madrid, Spain, 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, 3 Department of Medicine, Complutense University, Madrid, Spain

Abstract

Background: Essential tremor (ET) is one of the most common neurological disorders among adults, and is the most common of the many tremor disorders. It has classically been viewed as a benign monosymptomatic condition, yet over the past decade, a growing body of evidence indicates that ET is a progressive condition that is clinically heterogeneous, as it may be associated with a spectrum of clinical features, with both motor and non-motor elements. In this review, I will describe the most significant emerging milestones in research which, when taken together, suggest that ET is a neurodegenerative condition.

Methods: A PubMed search conducted in June 2014 crossing the terms “essential tremor” (ET) and “neurodegenerative” yielded 122 entries, 20 of which included the term “neurodegenerative” in the article title. This was supplemented by articles in the author’s files that pertained to this topic.

Results/Discussion: There is an open and active dialogue in the medical community as to whether ET is a neurodegenerative disease, with considerable evidence in favor of this. Specifically, ET is a progressive disorder of aging associated with neuronal loss (reduction in Purkinje cells) as well as other post-mortem changes that occur in traditional neurodegenerative disorders. Along with this, advanced neuroimaging techniques are now demonstrating distinct structural changes, several of which are consistent with neuronal loss, in patients with ET. However, further longitudinal clinical and neuroimaging longitudinal studies to assess progression are required.

Keywords: Essential tremor, neurodegenerative, clinical, pathology, review

Citation: Benito-León J. Essential tremor: A neurodegenerative disease? Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D8765CG0

* To whom correspondence should be addressed. E-mail: jbenitol67@gmail.com

Introduction

Neurodegenerative diseases are chronic, progressive disorders of the nervous system, often of long duration, with loss of specific vulnerable neuronal populations in the central and peripheral nervous system due to intrinsic processes rather than an identifiable outside influence (e.g., vascular, autoimmune), and they are often associated with gliosis and typical cytoskeletal protein aggregates.1

Essential tremor (ET) is one of the most common neurological disorders among adults, and is the most common of the many tremor disorders.2,3 ET is a widespread condition, affecting people of all races and cultures, from the remote Eastern Highlands of Papua, New Guinea, to the urban area of Madrid, Spain (NEDICES study, a population-based study).4–6 Its most recognizable clinical feature is an 8–12 Hz kinetic tremor of the arms (i.e., tremor during voluntary movement), which often is later accompanied by head and voice tremors.7–10 The traditional view of ET as a monosymptomatic condition is being replaced as a spectrum of clinical features, with both motor and non-motor elements, including ataxia, parkinsonism, cognitive impairment, dementia, personality disturbances, depressive symptoms, sensory abnormalities (e.g., mild olfactory dysfunction and hearing impairment), dysfunction of the upper respiratory airways, voice disturbances, and sleep disorders increasingly being documented.11–25 Furthermore, recent histopathological and neuroimaging studies in ET have demonstrated several distinctive structural changes, including neuronal loss.7–26

With increasing data emerging from these new clinical, neuroimaging, and pathological studies, a crucial question arises. Is ET
neurodegenerative? The idea that ET could be neurodegenerative is not novel. In the landmark paper by Critchley and Greenfield, published in 1948, the authors wrote: “Although anatomical proof is as yet lacking, there are at least a number of clinical points to make question whether “essential tremor” may not, at times any rate, represent an incomplete or a premature variant of one of the cerebellar atrophies.”30 Although not further elaborated on by those authors, these clinical characteristics include its insidious onset, association with advanced aging (i.e., both prevalence and incidence rates increase with age), gradually progressive nature, and the presence of “cerebellar” features (e.g., intention tremor and ataxia) on examination.29 Indeed, these are many clinical features typical of neurodegenerative diseases of the cerebellum.

In this review, I will discuss the most significant milestones in ET research, which, when taken together, suggest that ET is a neurodegenerative condition.

Methods

A PubMed search conducted in June 2014 crossing the terms “essential tremor” (ET) and “neurodegenerative” yielded 122 entries, 20 of which included the term “neurodegenerative” in the article title. This was supplemented by articles in the author’s files that pertained to this topic. Of note is that a recent review of the 100 most cited papers published in 1948, the authors wrote: “Although anatomical proof is as not novel. In the landmark paper by Critchley and Greenfield, published in 1948, the authors wrote: “Although anatomical proof is as yet lacking, there are at least a number of clinical points to make question whether “essential tremor” may not, at times any rate, represent an incomplete or a premature variant of one of the cerebellar atrophies.”30 Although not further elaborated on by those authors, these clinical characteristics include its insidious onset, association with advanced aging (i.e., both prevalence and incidence rates increase with age), gradually progressive nature, and the presence of “cerebellar” features (e.g., intention tremor and ataxia) on examination.29 Indeed, these are many clinical features typical of neurodegenerative diseases of the cerebellum.

In closing, the lack of empiric evidence as well as the new emerging data on the neurodegenerative model of ET (as discussed next) have now called the olivary model into question.45

The neurodegenerative model

Clinical studies

As with other neurodegenerative diseases, such as Parkinson’s disease (PD) or Alzheimer’s disease (AD),46–49 the incidence of ET increases with age.50 In a study of a multiethnic community in northern Manhattan, New York, more than one in five individuals in the oldest age group (≥95 years of age) had this disease.21 ET is a progressive disorder, which worsens over time in most patients.7–9 Several processes could contribute in the progression of symptoms in ET, including the inherent worsening of the underlying disease with increasing disease duration and the effects of aging on the nervous system, yet there are few prospective studies on ET that have attempted to identify the variables that influence progression of ET.52–56 Interestingly, disease duration and age are independently associated with tremor severity in ET.57 This suggests that the reported increase in tremor severity in ET may be related to the inherent worsening of the disease with increasing duration, and that this is independent of age and age-related processes like neuronal attrition and change in tremor frequency.57 In a large clinical sample, older age of onset was associated with more rapid tremor progression.58 In a brain bank, older age of onset was associated with more degenerative pathology in the cerebellum.58 Only a few longitudinal studies have actually attempted to quantify the rate of actual tremor progression.52–56 An increase in tremor amplitude of about 30% in a period of 4 years and a decrease of frequency by approximately 0.06 to 0.08 Hz/year together with a reduction in tremor frequencies has been observed by accelerometry and surface electromyography.55 A few longitudinal data51,56 have described a small, but significant, increase in tremor severity in ET patients, estimated as 12% per year from baseline evaluation in one clinical series,29 and an average annual increase in tremor severity from baseline between 3.1% and 5.3% in another recent series followed for ≥5 years.56

In addition, disease progression is not only characterized by spreading of tremor to the head (neck), which eventually occurs in approximately 40% of patients,59 but also by the occurrence of...
abnormalities of cerebellar function in ET.\textsuperscript{7–9} The wide spectrum of cerebellar symptoms that may be observed in ET, include the presence of intentional tremor,\textsuperscript{7–9,60} gait ataxia,\textsuperscript{11,38–40} dysarthria,\textsuperscript{61} oculomotor abnormalities,\textsuperscript{82} as well as deficits in hand-eye coordination.\textsuperscript{83} Specifically, gait disturbances (i.e., ataxia) are seen more frequently in ET patients with longer disease duration who are at an advanced stage of ET and among those cases with midline (e.g., cranial) tremors.\textsuperscript{11,64–67} Of further interest is the observation that gait abnormalities in ET can temporarily improve with ethanol intake.\textsuperscript{68} In one study, the ingestion of ethanol to a mean blood level of 0.45% led to a transient but significant improvement of ataxia in ET patients yet produced a worsening of gait parameters in controls.\textsuperscript{68} Ethanol binds to the gamma-aminobutyric acid (GABA) receptor, thereby facilitating GABAergic neurotransmission.\textsuperscript{7–9} One should bear in mind that the neuropathological deficit involving ataxia and tremor could be the same, that is a deficit in GABA cerebellar neurotransmission.\textsuperscript{7–9}

Rest tremor of the arms is observed in one in five ET patients and also it may be an early sign of ET.\textsuperscript{69} In one tertiary referral center, the patients with rest tremor had kinetic tremor that was more severe, more disseminated, and of longer duration than ET patients without rest tremor.\textsuperscript{69} Although the pathogenesis of rest tremor in ET is unknown,\textsuperscript{70} it could be related to pathologic spreading to extracerebellar circuits in patients with severe, long-standing, and disseminated disease. Alternatively, it may result from a pathological interaction between the basal ganglia and the cerebello-thalamo-cortical circuits.\textsuperscript{71}

As the heterogeneity of ET becomes more evident, researchers have expressed increased interest in exploring the possibility that there are associated findings (e.g., motor and non-motor manifestations) associated with this disorder, and that it may be associated with other neurodegenerative diseases (e.g., PD or AD).\textsuperscript{7–9,72}

The weight of emerging evidence is indicating that ET is also associated with a series of non-motor manifestations, including cognitive deficits,\textsuperscript{14,15,73–76} mild cognitive impairment,\textsuperscript{15} dementia,\textsuperscript{16,17,77} personality changes,\textsuperscript{18} depressive symptoms,\textsuperscript{19} possible mild olfactory dysfunction,\textsuperscript{20,76,79} hearing impairment,\textsuperscript{21,22} and sleep disorders.\textsuperscript{10,81} Several of these non-motor manifestations are also seen in many other neurodegenerative conditions, such as PD and Huntington’s disease, among others.\textsuperscript{82,83}

As in other neurodegenerative diseases,\textsuperscript{84,85} cognitive deficits, mainly in frontal-executive function and memory, have been reported to occur in ET patients in a range of independent studies.\textsuperscript{14,15,73–76} Including a population-based case-control study of largely treatment-naïve ET patients nested in the NEDICES study.\textsuperscript{15} Taken together, these studies indicate that a frontosubcortical-type dysfunction occurs in some ET patients.\textsuperscript{14,15,73–76} Overall, the degree of cognitive impairment in ET is mild and is thought to be due to a dysfunction in the dorsolateral prefrontal cortex and in the inferior parietal cortex, including the cerebral–cerebellar loop.\textsuperscript{98} In the NEDICES study, baseline cognitive test scores were lower in non-demented ET cases than non-demented controls;\textsuperscript{76} moreover, during the 3-year follow-up period, these scores declined at a rate that was seven-times faster in ET cases.\textsuperscript{76}

The NEDICES study also provided evidence that cognitive deficits in premotor ET (that is, ET cases who underwent neuropsychological evaluations at a baseline visit prior to the onset of their tremor) are not static, and that they appear to be progressing at a faster rate than in elders who do not develop this disease.\textsuperscript{97} In addition, an association between elderly-onset ET and prevalent mild cognitive impairment was demonstrated in the NEDICES study.\textsuperscript{13} In line with this, in the NEDICES study, elderly-onset ET was found to be associated with prevalent dementia.\textsuperscript{16} ET cases with tremor onset after 65 years of age were 70% more likely to have dementia than were similarly aged controls.\textsuperscript{16} In the follow-up of the same population, ET cases with tremor onset after age 65 years were twice as likely to develop incident dementia than were controls, whereas ET cases with tremor onset <65 years of age and controls were equally to develop incident dementia.\textsuperscript{17} In a second population-based study of elders in New York, ET was also associated with both increased odds of prevalent dementia and increased risk of incident dementia,\textsuperscript{77} with odds ratios and relative risks similar to those reported in the NEDICES study.\textsuperscript{77} In both studies, the large majority of subjects with dementia had AD.\textsuperscript{16,77} Although additional studies are needed, these two studies suggest that the presence of dementia in ET appears to be greater than expected for age and that there are links between ET and AD.\textsuperscript{16,77} In a recent study that included 40 ET patients who were free of dementia clinically and without AD on post-mortem examination and 32 age-matched controls, ET patients had a higher Braak neurofibrillary stage, but similar scores for neuritic plaques.\textsuperscript{80} ET may predispose individuals to accumulate more widespread cellular tau aggregates, and thus tau could play a central role in the cognitive impairment that can accompany ET.\textsuperscript{80}

The relationship between ET and PD has been a subject of reviews and debate for a long time, but there is now growing evidence that the two disorders are related, at least in some patient populations.\textsuperscript{12,89–92} Clinical series, follow-up studies of ET patients, and case-control and genetic epidemiological studies indicate that ET is associated with increased risk for PD.\textsuperscript{19} In addition, some neuroimaging studies and neuropathological reports suggest an association between the two diseases. Some ET patients may have a circumscribed form of Lewy body disease, and the secondary development of PD may represent a spread of those Lewy bodies in the brainstem.\textsuperscript{91} ET patients may have some degree of bradykinesia. In a recent study, ET patients showed impaired motor performance, at least in some tasks, such as rapid repetitive finger movements (finger tapping and frequency) and visual reaction time (impairment was not related with tremor severity).\textsuperscript{93} The link between ET and PD has been formally quantified in the NEDICES study, which demonstrated that the risk of developing incident PD was 4.3 times higher in ET cases than in age-matched controls without ET.\textsuperscript{12}

Depressive symptoms might be more prevalent in ET than in the population,\textsuperscript{19} as is seen in other neurodegenerative diseases, such as PD.\textsuperscript{94} In the NEDICES study, prevalent ET cases were twice as likely
as controls to report depression and three times more likely to be taking antidepressant medications. In prospective analyses of this study, baseline self-reported depression was associated with incident ET. These prospective data suggest that the mood disorder in ET may be more than a secondary response to disease manifestations; this mood disorder may be a primary feature of the underlying disease.

Mild olfactory dysfunction has been detected in ET patients in several studies, but not in others. When observed, this dysfunction is, on average, milder than that observed in patients with PD. As in PD, this possible dysfunction does not correlate with disease duration or severity, indicating that it occurs early in the disease process.

Hearing impairment in ET has been reported in two case–control studies. At a tertiary referral center, ET was associated with hearing impairment, as shown by both subjective and objective measures of hearing loss. Similarly, in the NEDICES study, ET patients reported more hearing impairment than did matched controls. The basis for this possible hearing impairment is unknown. However, both central and peripheral nervous system mechanisms have been suggested.

Sleep dysregulation is often described in neurodegenerative diseases. The association between sleep dysregulation and ET has been assessed in several studies. Adler et al. compared Epworth Sleepiness Scale scores (ESS) in 53 ET cases to 49 PD cases and 175 normal controls, and noted no ET case–control difference; in that study, ESS scores in ET were intermediate between normal controls and PD but far more similar to those of normal controls. Chandran et al. found a marked difference in Pittsburgh Sleep Quality Index (PSQI) scores in 50 ET cases as compared with 50 controls, yet no difference in ESS scores. Gerbin et al. compared the ESS and the PSQI scores in 120 ET cases, 120 normal controls, and 40 PD cases. The ET case–control difference was not significant, yet in a test for trend, PD cases had the highest PSQI score, followed by ET (intermediate), and lowest scores in controls. Finally, in NEDICES short sleep duration was associated with an increased risk of ET.

Similar to PD and AD, the two paradigmatic neurodegenerative diseases, there is a proportion of the ET patients with a clear family history of disease, which is lower in PD and AD, and higher in ET. The risk of action tremor and ET is increased in the relatives of PD patients, particularly when they have tremor-dominant PD.

These findings suggest that PD and ET may share familial susceptibility factors.

Pathological evidence

There is a marked and continued rise in ET prevalence and incidence in advanced ages. ET has an insidious onset and then follows a gradual yet progressive clinical course. The clinical constellation, discussed in the previous section, is somewhat compelling; however, none of the clinical features in isolation is specific to neurodegenerative diseases. On a tissue-based level, the evidence is more compelling. A fundamental question about the neurodegenerative nature of a neurological disorder is whether there are histopathological changes in the brain. Selective involvement of an anatomically and physiologically related system of neurons (Purkinje cells), has been reported in ET cases in recent series. Until several years ago, only 25 reported post-mortem examinations in ET were available, many of which were published 50–100 years ago, and few of which described relevant brain structures in detail. A further problem was the absence of any age-matched control brains for comparison. The Essential Tremor Centralized Brain Repository at Columbia University (New York, NY) was established in 2003 to prospectively collect and study in detail the brains of individuals with ET, and to compare them with matched control brains.

A preliminary analysis, including 10 ET cases and 12 controls, demonstrated that ET may be pathologically heterogeneous. The number of torpedoes (a marker of axonal damage or regenerative process) and Bergmann glia was increased in ET cases; six cases (60%) had Lewy bodies vs. two controls (16.7%); four of these six had an atypical distribution of brainstem Lewy bodies. Overall, ET cases clustered into two groups: those with cerebellar degenerative changes (n=4) and those with brainstem Lewy bodies (Lewy body variant of ET; n=6), raising the possibility that some ET cases have a form of Lewy body disease. Of note, the presence of torpedoes is not specific to ET, and is observed in other well-known neurodegenerative conditions, such as progressive supranuclear palsy, dentatorubropallidoluysian atrophy, and fragile X-associated tremor/ataxia.

A more relevant study by Axelrad et al. demonstrated a reduction in Purkinje cell number in the brains of patients with ET who did not have Lewy bodies. These data further support the view that the cerebellum is anatomically, as well as functionally, abnormal in these ET cases. Recently, an abundance of torpedoes has been shown in the cerebellar vermis of ET brains, mainly in patients with neck, voice, and jaw tremors.

In the Essential Tremor Centralized Brain Repository of New York, which compared 33 ET cases to 21 controls, the mean number of Purkinje cells per 100× field was reduced in ET cases and there were approximately seven times as many torpedoes in ET cases as well. Two cases also had degeneration of the dentate nucleus. Other structural abnormalities in ET cases were Purkinje cell heterotopias and Purkinje cell dendrite swellings as well as hypertrophy of basket cell axonal processes. Eight (24.2%) of the 33 ET brains had Lewy bodies in the brainstem, mainly in the locus ceruleus, and normal cerebellum. By contrast, two recent studies reported no reduction in Purkinje cells in ET or have concluded that there is no clear distinction between ET, PD, and normal control subjects in the number of Purkinje cells. However, there are a number of significant methodological problems with the design of these studies, and these issues cast considerable doubt on the validity of the reported results.

In summary, clearly identifiable structural changes (i.e., Purkinje cell loss, Lewy bodies) have been observed in the brains of ET patients. These changes are not uniform and seem to follow several patterns, localizing to the cerebellum itself or to a collection of brainstem structures in detail.
neurons in the locus ceruleus that synapse directly with Purkinje cells.\textsuperscript{20} Furthermore, these changes are similar to those seen in degenerative diseases.\textsuperscript{20}

**Neuroimaging evidence**

In contrast to post-mortem studies, neuroimaging studies provide a non-invasive method to examine structural changes in living patients who have not yet arrived at an end-stage of disease. A broad array of neuroimaging methods used in a rising tide of studies, including functional magnetic resonance imaging (fMRI) studies,\textsuperscript{114} positron emission tomography studies,\textsuperscript{115,116} \textsuperscript{1}H magnetic resonance spectroscopic imaging studies,\textsuperscript{117–119} diffusion tensor imaging studies,\textsuperscript{120–122} voxel-based morphometry studies,\textsuperscript{26,123,124} and studies using other automated volumetric methods,\textsuperscript{125} now indicate the presence not only of functional and metabolic abnormalities in the ET cerebellum, but of structural abnormalities in both the cerebellar gray and white matter as well.\textsuperscript{126}

A reduction in cerebellar cortical N-acetyl-L-aspartate (NAA) and total choline, relative to total creatine (tCR), indicates that there is neuronal damage or loss in ET, suggesting that ET may be a neurodegenerative disease.\textsuperscript{117–119} Voxel-based morphometry studies using 1.5 T MRI have led to contradictory results;\textsuperscript{123,124} however, by using 3 T MRI, structural white and gray abnormalities may be detected in ET patients in both the cerebellum and different cerebral areas. Specifically, Benito-León et al.\textsuperscript{26} detected white matter changes in several areas (right cerebellum, left medulla, right parietal lobe, and right limbic lobe) and gray matter changes in several areas as well (bilateral cerebellum, bilateral parietal lobes, right frontal lobe, and right insula) in 19 ET patients vs. 20 controls. In line with these results,\textsuperscript{26} another recent report of 20 ET patients and 20 controls showed widespread areas of atrophy in both the cerebellum and cerebral gray matter, as well as a relationship between gray matter atrophy and tremor severity score, which supports the current concept of the progressive and diffuse nature of ET.\textsuperscript{127}

Diffusion-weighted imaging is used to search for evidence of tissue integrity abnormalities; although a previous study did not detect any significant changes between 10 ET patients and 10 controls, another study involving 10 ET patients and eight controls\textsuperscript{122} showed a significantly reduced fractional anisotropy in the anterolateral portion of the right pons and decreased fractional anisotropy in the bilateral cerebellum, left retrotrubral area of the midbrain, and bilateral deep white matter, including the orbitofrontal, lateral frontal, parietal, and temporal white matter. Further, by means of 3 T MRI, significant reduction of fractional anisotropy was reported in the dentate nucleus and superior cerebellar peduncle of patients with familial ET;\textsuperscript{121} additionally, among patients with familial ET, those with longer disease duration showed fractional anisotropy values in the dentate nucleus lower than those with shorter disease duration. Finally, Klein et al.,\textsuperscript{120} by means of a whole-brain analysis with tract-based spatial statistic, confirmed by voxel-wise analysis, circumspect pathology of the inferior cerebellar peduncles. Moreover, increased diffusivity in white matter structures of both hemispheres suggests widespread alterations of fiber integrity in motor and non-motor networks in ET patients.\textsuperscript{120}

Finally, in a study using volumetric data obtained with automated segmentation of subcortical and cerebellar structures, reduction of cerebellar volume in patients was observed in patients with head tremor when compared with healthy controls, after controlling for intracranial volume was observed.\textsuperscript{125}

**Conclusions**

The neurodegenerative hypothesis of ET on the surface seems at odds with the early onset and clinically slow and heterogeneous progression of ET in some patients.\textsuperscript{126} Indeed, some researchers have advocated for an alternative pathophysiological explanation for ET based on central oscillating pacemakers.\textsuperscript{128} This hypothesis would not require structural changes in the anatomical organization or connectivity of the cerebello-thalamo-corticero-cerebellar loops.\textsuperscript{128} However, the hypothesis is purely conjectural and based on little if any empiric evidence. ET is a progressive, aging-associated condition, associated with cell loss (reduction in Purkinje cell number in properly designed studies) and other types of changes (Lewy body formation) that traditionally occur in neurodegenerative disorders. Further, the overwhelming data from different independent study groups, including new pathological and MRI findings, as well as the constellation of non-motor findings, all present in the same disease, similar to other neurodegenerative diseases, suggest that ET is a neurodegenerative disease.\textsuperscript{129,130} In addition, the considerable evidence for an association between ET and PD and the fact that elderly-onset ET increases the risk of developing AD nearly twofold suggests that ET may share pathogenic mechanisms with these disorders. Finally, there are no reported cases of spontaneous remission of ET; a disease condition whose pathophysiology was based on a disorder of a central oscillating pacemaker might result in either a spontaneous improvement or disappearance of the same. However, further longitudinal clinical and neuroimaging longitudinal studies to assess progression are required.

**References**

1. Victor M, Ropper AH, Adams RD. Adams and Victor’s principles of neurology, 7th ed. New York: Medical Pub. Division, McGraw-Hill; 2001.
2. Benito-León J. How common is essential tremor? Neuroepidemiology 2009; 32:215–216, doi: http://dx.doi.org/10.1159/000195692.
3. Benito-León J. Essential tremor: One of the most common neurodegenerative diseases? Neuroepidemiology 2011;36:77–78, doi: http://dx.doi.org/10.1159/000325372.
4. Benito-León J, Bermejo-Pareja F, Morales JM, Vega S, Molina JA. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003;18:389–394, doi: http://dx.doi.org/10.1002/mds.10376.
5. Hornabrook RW, Nagurney JT. Essential tremor in Papua, New Guinea. Brain 1976;99:659–672, doi: http://dx.doi.org/10.1093/brain/99.4.659.
6. Romero JP, Benito-León J, Bermejo-Pareja F. The NEDICES Study: Recent Advances in the Understanding of the Epidemiology of Essential Tremor. Tremor Other Hyperkinet Mov 2012;2 http://tremorjournal.org/article/view/70.
7. Benito-León J, Louis ED. Clinical update: Diagnosis and treatment of essential tremor. *Lancet* 2007;369:1152–1154, doi: http://dx.doi.org/10.1016/S0140-6736(07)60544-3.

8. Benito-León J, Louis ED. Update on essential tremor. *Minerva Med* 2011; 102:417–439.

9. Benito-León J, Louis ED. Essential tremor: Emerging views of a common disorder. *Nat Clin Pract Neurol* 2006;2:666–678, doi: http://dx.doi.org/10.1038/ncpneuro0347.

10. Labiano-Fontcuberta A, Benito-León J. [Essential tremor: Update.]. *Med Clin (Barc)* 2013;140:128–133, doi: 10.1016/j.medcli.2012.07.005.

11. Louis ED, Río E, Rao AK. Tandem gait performance in essential tremor: Clinical correlates and association with midline tremors. *Mov Disord* 2010;25:1633–1638, doi: http://dx.doi.org/10.1002/mds.23144.

12. Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: A population based study. *J Neurol Neurosurg Psychiatry* 2009;80:423–425, doi: http://dx.doi.org/10.1136/jnnp.2008.147223.

13. Benito-León J, Louis ED, Mitchell AJ, Bermejo-Pareja F. Elderly-onset essential tremor and mild cognitive impairment: A population-based study (NEDICES). *J Alzheimers Dis* 2011;23:727–735.

14. Benito-León J, Louis ED, Sánchez-Ferro A, Bermejo-Pareja F. Rate of cognitive decline during the premotor phase of essential tremor: A prospective study. *Neurology* 2013;81:60–66, doi: http://dx.doi.org/10.1212/WNL.0b013e318297ef2b.

15. Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Population-based case-control study of cognitive function in essential tremor. *Neurology* 2006;66:69–74, doi: http://dx.doi.org/10.1212/01.wnl.0000192393.05850.cc.

16. Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Elderly-onset essential tremor is associated with dementia. *Neurology* 2006;66:1500–1505, doi: http://dx.doi.org/10.1212/01.wnl.0000216134.38617.de.

17. Bermejo-Pareja F, Louis ED, Benito-León J, Neurological Disorders in Central Spain Study Group. Risk of incident dementia in essential tremor: A population-based study. *Mov Disord* 2007;22:1573–1580, doi: http://dx.doi.org/10.1002/mds.21553.

18. Chatterjee A, Jurwicz EC, Applegate LM, Louis ED. Personality in essential tremor: Further evidence of non-motor manifestations of the disease. *J Neurol Neurosurg Psychiatry* 2004;75:958–961, doi: http://dx.doi.org/10.1136/jnnp.2004.035716.

19. Louis ED, Benito-León J, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Self-reported depression and anti-depressant medication use in essential tremor: Cross-sectional and prospective analyses in a population-based study. *Eur J Neurol* 2007;14:1138–1146.

20. Louis ED, Bromley SM, Jurwicz EC, Warner D. Olfactory dysfunction in essential tremor: A deficit unrelated to disease duration or severity. *Neurology* 2002;59:1631–1633, doi: http://dx.doi.org/10.1212/01.WNL.0000353590.85208.F2.

21. Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. *Neurology* 2003;61:1093–1097, doi: http://dx.doi.org/10.1212/01.WNL.0000086376.04750.AF.

22. Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Reported hearing impairment in essential tremor: A population-based case-control study. *Neuropathology* 2007;27:213–217, doi: http://dx.doi.org/10.11159/000112463.

23. Jiménez-Jiménez FJ, Izquierdo-Alonso JL, Cabrera-Valdivia F, Mansilla-Lesmes M, Martínez-Martín P, Serrano-Iglesias JA. [ Dysfunction of the upper respiratory airways in patients with essential tremor]. *Presse Med* 1995;24:1152–1156.

24. Gamboa J, Jiménez-Jiménez FJ, Nieto A, et al. Acoustic voice analysis in patients with essential tremor. *J Voice* 1998;12:444–452.

25. Benito-León J, Louis ED, Bermejo-Pareja F. Short sleep duration heralds essential tremor: A prospective, population-based study. *Mov Disord* 2013;28:1700–1707, doi: http://dx.doi.org/10.1002/mds.25590.

26. Benito-León J, Álvarez-Linera J, Hernández-Tamames JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Louis ED. Brain structural changes in essential tremor: Voxel-based morphometry at 3-Tesla. *J Neurol Sci* 2009;287:138–142, doi: http://dx.doi.org/10.1016/j.jns.2009.08.037.

27. Bhalsing KS, Upadhayay N, Kumar KJ, et al. Association between cortical volume loss and cognitive impairments in essential tremor. *Eur J Neurol* 2014;21:874–883, doi: 10.1111/ene.12399.

28. Louis ED. Essential tremor: Evolving clinicopathological concepts in an era of intensive post-mortem enquiry. *Lancet Neurol* 2010;9:613–622, doi: http://dx.doi.org/10.1016/S1474-4422(10)70090-9.

29. Crüschley M. Observations on essential (heredo-familial) tremor. *Brain* 1949;72:113–139, doi: http://dx.doi.org/10.1093/brain/72.2.113.

30. Benito-León J, Louis ED. The top 100 cited articles in essential tremor. *Tremor Other Hyperkinet Mov* 2013;3: http://tremorjournal.org/article/view/186.

31. Llinars R, Vollkind RA. The olivo-cerebellar system: Functional properties as revealed by harmaline-induced tremor. *Exp Brain Res* 1973;18:69–87, doi: http://dx.doi.org/10.1007/BF00296557.

32. Deuschl G, Elble RJ. The pathophysiology of essential tremor. *Neurology* 2000;54:S14–20, doi: http://dx.doi.org/10.1212/WNL.54.4.S14A.

33. Martin FG, Thu Le A, Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. *Mov Disord* 2005;20:298–305, doi: http://dx.doi.org/10.1002/mds.20331.

34. Louis ED, Benito-León J, Moreno-Garcia S, et al. Blood harmine (1-methyl-9H-pyrido[3,4-b]indole) concentration in essential tremor cases in Spain. *Neurotoxicology* 2013;34:264–268, doi: http://dx.doi.org/10.1016/j.neuro.2012.09.004.

35. Handforth A. Harmaline tremor: Underlying mechanisms in a potential animal model of essential tremor. *Tremor Other Hyperkinet Mov* 2012;2: http://tremorjournal.org/article/view/92.

36. O’Hearn E, Molliver ME. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: A model of indirect, trans-synaptic excitotoxicity. *J Neurosci* 1997;17:3828–3841.

37. Louis ED. Understanding essential tremor: Progress on the biological front. *Curr Neurol Neurosci Rep* 2014;14:450, doi: http://dx.doi.org/10.1007/s11910-014-0450-z.

38. O’Hearn E, Molliver ME. Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine. *Neuroscience* 2004;127:373–383, doi: http://dx.doi.org/10.1016/j.neuroscience.2004.04.058.
39. de Oliveira RB, Howlett MC, Gravina FS, et al. Pacemaker currents in mouse locus coeruleus neurons. *Neuroscience* 2010;170:166–177, doi: http://dx.doi.org/10.1016/j.neuroscience.2010.06.028.

40. Penington NJ, Tuckwell HC. Properties of EA in a neuron of the dorsal raphe nucleus. *Brain Res* 2012;1449:60–68, doi: http://dx.doi.org/10.1016/j.brainres.2012.02.026.

41. Jahnson H, Llinas R. Ionic basis for the electro-responsiveness and oscillatory properties of guinea-pig thalamic neurones in vitro. *J Physiol* 1984; 349:227–247.

42. Hansen ST, Meera P, Otis TS, Pulst SM. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. *Hum Mol Genet* 2013;22:271–283, doi: http://dx.doi.org/10.1093/hmg/ddt247.

43. Wills AJ, Jenkins IH, Thompson PD, Finlley LJ, Brooks DJ. Red nuclear and cerebellar but no olivary activation associated with essential tremor: A positron emission tomographic study. *Ann Neurol* 1994;36:636–642, doi: http://dx.doi.org/10.1002/ana.410360413.

44. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. *Mov Disord* 2008;23:174–182, doi: http://dx.doi.org/10.1002/mds.21731.

45. Louis ED. Re-thinking the biology of essential tremor: From models to morphology. *Parkinsonism Relat Disord* 2014;20(Suppl 1):S88–93, doi: http://dx.doi.org/10.1016/S1353-8020(13)70023-3.

46. Benito-León J, Bermejo-Pareja F, Rodríguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. *Mov Disord* 2003;18:267–274, doi: http://dx.doi.org/10.1002/mds.10362.

47. Bermejo-Pareja F, Benito-León J, Vega S, et al. Consistency of clinical diagnosis of dementia in NEDICES: A population-based longitudinal study in Spain. *J Geriatr Psychiatry Neurol* 2004;17:246–255, doi: http://dx.doi.org/10.1177/08919887040170039794.

48. Benito-León J, Bermejo-Pareja F, Morales-Gonzalez JM, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. *Neurology* 2004;62:734–741, doi: http://dx.doi.org/10.1212/01.WNL.0000113727.73153.68.

49. Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Roman GC. Incidence and subtypes of dementia in three elderly populations of central Spain. *J Neurol Sci* 2008;264:63–72, doi: http://dx.doi.org/10.1016/j.jns.2007.07.021.

50. Benito-León J, Bermejo-Pareja F, Louis ED, Neurological Disorders in Central Spain Study Group. Incidence of essential tremor in three elderly populations of central Spain. *Neurology* 2005;64:1721–1725, doi: http://dx.doi.org/10.1212/01.WNL.00001852.70374.01.

51. Louis ED, Thawani SP, Andrews HF. Prevalence of essential tremor in a multiethnic, community-based study in northern Manhattan, New York, N.Y. *Neuropsychology* 2009;23:208–214.

52. Louis ED, Ford B, Barnes LF. Clinical subtypes of essential tremor. *Arch Neurol* 2000;57:1194–1198, doi: http://dx.doi.org/10.1001/archneur.57.8.1194.

53. Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: Predictors of disease progression in a clinical cohort. *J Neurol Neurosurg Psychiatry* 2006;77:1235–1237, doi: http://dx.doi.org/10.1136/jnnp.2005.086579.

54. Louis ED, Hernandez N, Ionita-Laza I, Ottman R, Clark LN. Does rate of progression run in essential tremor families? Slower vs. faster progressors. *Parkinsonism Relat Disord* 2013;19:363–366, doi: http://dx.doi.org/10.1016/j.parkreldis.2012.10.005.

55. Elble RJ. Essential tremor frequency decreases with time. *Neurology* 2000;55:1547–1551, doi: http://dx.doi.org/10.1212/WNL.55.10.1547.

56. Louis ED, Agnew A, Gillman A, Gerbin M, Viner AS. Estimating annual rate of decline: Prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases. *J Neurol Neurosurg Psychiatry* 2011;82:761–765, doi: http://dx.doi.org/10.1136/jnnp.2010.229740.

57. Louis ED, Jurewicz EC, Watner D. Community-based data on associations of disease duration and age with severity of essential tremor: Implications for disease pathophysiology. *Mov Disord* 2003;18:90–93, doi: http://dx.doi.org/10.1002/mds.10302.

58. Louis ED, Faust PL, Vonsattel JP, et al. Older onset essential tremor: More rapid progression and more degenerative pathology. *Mov Disord* 2009;24:1606–1612, doi: http://dx.doi.org/10.1002/mds.22570.

59. Louis ED. When do essential tremor patients develop head tremor? Influences of age and duration and evidence of a biological clock. *Neuropathology* 2013;41:110–115, doi: http://dx.doi.org/10.11159/000351698.

60. Deuschl G, Wenzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor. *Brain* 2000;123 (Pt 8):1568–1570, doi: http://dx.doi.org/10.1093/brain/123.8.1568.

61. Kronenbuehler M, Konczak J, Ziegler W, et al. Balance and motor speech impairment in essential tremor. *Cerebellum* 2009;8:389–398, doi: http://dx.doi.org/10.1002/cer.1011-v.

62. Helmchen C, Hagenow A, Miesner J, et al. Eye movement abnormalities in essential tremor may indicate cerebellar dysfunction. *Brain* 2003;126:1319–1332, doi: http://dx.doi.org/10.1093/brain/awg132.

63. Trillenberg P, Fuhrer J, Sprenger A, et al. Eye-hand coordination in essential tremor. *Mov Disord* 2006;21:373–379, doi: http://dx.doi.org/10.1002/mds.20729.

64. Stolze H, Petersen G, Raethjen J, Wenzelburger R, Deuschl G. The gait disorder of advanced essential tremor. *Brain* 2001;124:2278–2286, doi: http://dx.doi.org/10.1093/brain/124.11.2278.

65. Raio AK, Uddin A, Gillman A, Louis ED. Cognitive motor interference during dual-task gait in essential tremor. *Gait Posture* 2013;38:403–409, doi: http://dx.doi.org/10.1016/j.gaitpost.2013.01.006.

66. Louis ED, Galecki M, Rao AK. Four essential tremor cases with moderately impaired gait: How impaired can gait be in this disease? *Tremor Other Hyperkinet Mov* 2013;3: http://tremorjournal.org/article/view/200.

67. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. *Mov Disord* 1994;9:193–196, doi: http://dx.doi.org/10.1002/mds.870900212.

68. Klee S, Stolze H, Gensing K, Volkmann J, Wenzelburger R, Deuschl G. Influence of alcohol on gait in patients with essential tremor. *Neurology* 2005;65:96–101, doi: http://dx.doi.org/10.1212/01.wnl.0000167530.97413.1f.

69. Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in patients with essential tremor: Prevalence, clinical correlates, and electrophysiologic characteristics. *Arch Neurol* 2003;60:405–410, doi: http://dx.doi.org/10.1001/archneur.60.3.405.
70. Louis ED, Asahere N, Agnew A, et al. Rest tremor in advanced essential tremor: A post-mortem study of nine cases. *J Neurol Neurosurg Psychiatry* 2011;82:261–265, doi: http://dx.doi.org/10.1136/jnnp.2010.215681.

71. Wu T, Hallett M. The cerebellum in Parkinson’s disease. *Brain* 2013;136:696–709, doi: http://dx.doi.org/10.1093/brain/ aws560.

72. Benito-León J. Essential tremor: From a monosymptomatic disorder to a more complex entity. *Neuropediatrics* 2008;39:191–192, doi: http://dx.doi.org/10.1159/000154933.

73. Troster AT, Fields JA, Pahwa R, et al. Neuropsychological and quality of life outcome after thalamic stimulation for essential tremor. *Neurology* 1999;53:1774–1780, doi: http://dx.doi.org/10.1212/WNL.53.8.1774.

74. Louis ED, Benito-León J, Vega-Quiróga S, Bermejo-Pareja F. Neurological Disorders in Central Spain Study Group. Cognitive and motor functional activity in non-demented community-dwelling essential tremor cases. *J Neurol Neurosurg Psychiatry* 2010;81:997–1001, doi: http://dx.doi.org/10.1136/jnnp.2009.202838.

75. Bermejo-Pareja F, Puertas-Martín V. Cognitive features of essential tremor: A review of the clinical aspects and possible mechanistic underpinnings. *Tremor Other Hyperkinet Mov* 2012;2: http://www.tremorjournal.org/index.php/tremor/article/view/74.

76. Louis ED, Benito-León J, Vega-Quiróga S, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Faster rate of cognitive decline in essential tremor cases than controls: A prospective study. *Eur J Neurol* 2010;17:1291–1297.

77. Thawani SP, Schupp N, Louis ED. Essential tremor is associated with dementia: Prospective population-based study in New York. *Neurology* 2009;73:621–625, doi: http://dx.doi.org/10.1212/WNL.0b013e3181b389f1.

78. Shah M, Muhammed N, Findley LJ, Hawkes CH. Olfactory tests in the diagnosis of essential tremor. *Parkinsonism Relat Disord* 2008;14:563–568, doi: http://dx.doi.org/10.1016/j.parkreldis.2007.12.006.

79. Applegate LM, Louis ED. Essential tremor: Mild olfactory dysfunction in a cerebellar disorder. *Parkinsonism Relat Disord* 2005;11:399–402, doi: http://dx.doi.org/10.1016/j.parkreldis.2005.03.003.

80. Chandran V, Pal PK, Reddy JY, Thennarasu K, Yadav R, Shivashankar N. Non-motor features in essential tremor. *Acta Neurol Stand* 2012;125:332–337, doi: http://dx.doi.org/10.1111/j.1600-0404.2011.01573.x.

81. Gerbin M, Viner AS, Louis ED. Sleep in essential tremor: A comparison with normal controls and Parkinson’s disease patients. *Parkinsonism Relat Disord* 2012;18:279–284, doi: http://dx.doi.org/10.1016/j.parkreldis.2011.11.004.

82. Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson’s disease: Expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. *Neural Clin* 2013;31:S1–16, doi: http://dx.doi.org/10.1016/j.necl.2013.04.013.

83. Jacobs DH, Huber SJ. The role of the caudate in nonmotor behaviors in Huntington’s disease. *Behav Neurol* 1992;5:205–214, doi: http://dx.doi.org/10.1155/1992/926819.

84. Benito-León J, Louis ED, Posada IJ, et al. Population-based case-control study of cognitive function in early Parkinson’s disease (NEDICES). *J Neurol Sci* 2011;310:176–182, doi: http://dx.doi.org/10.1016/j.jns.2011.06.054.

85. Kobal J, Melik Z, Cankar K, Strulc M. Cognitive and autonomic dysfunction in presymptomatic and early Huntington’s disease. *J Neurol* 2014;261:1119–1125.

86. Cerasa A, Passamonti L, Novellino F, et al. Fronto-parietal over-activation in patients with essential tremor during Stroop task. *Neuroreport* 2010;21:148–151, doi: http://dx.doi.org/10.1097/WNR.0b013e328333b42e.

87. Benito-León J, Louis ED, Sánchez-Ferro A, Bermejo-Pareja F. Rate of cognitive decline during the premotor phase of essential tremor: A prospective study. *Neurology* 2013;81:60–66, doi: http://dx.doi.org/10.1212/WNL.0b013e318297fe2b.

88. Pan JJ, Lee M, Honig LS, Vonsattel JP, Faust PL, Louis ED. Alzheimer’s-related changes in non-demented essential tremor patients vs. controls: Links between tau and tremor? *Parkinsonism Relat Disord* 2014;20:655–658, doi: 10.1016/j.parkreldis.2014.03.003.

89. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martin E, Agundez JA. The relationship between Parkinson’s disease and essential tremor: Review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. *Tremor Other Hyperkinet Mov* 2012;2: http://www.tremorjournal.org/index.php/tremor/article/view/75.

90. Labiano-Fontcuberta A, Benito-León J. [Essential tremor and Parkinson’s disease: Are they associated?]. *Rev Neurol* 2012;55:479–489.

91. Louis ED, Ottman R. Is there a one-way street from essential tremor to Parkinson’s disease? Possible biological ramifications. *Eur J Neurol* 2013;20:1440–1444.

92. Wurster I, Abaza A, Brockmann K, Liepert-Scarfone I, Berg D. Parkinson’s disease with and without preceding essential tremor-similar phenotypes: A pilot study. *J Neurol* 2014;261:1884–1888, doi: 10.1007/s00415-014-7285-z.

93. Jiménez-Jiménez FJ, Rubio I, Alonso-Navarro H, et al. Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. *Eur J Neurol* 2010;17:152–159.

94. Ossowska K, Lorenz-Koci E. Depression in Parkinson’s disease. *Pharmacol Rep* 2013;65:1545–1557, doi: http://dx.doi.org/10.1016/S1873-1140(13)71516-0.

95. Louis ED, Jurewicz EC. Olfaction in essential tremor patients with and without isolated rest tremor. *Mov Disord* 2003;18:1307–1309, doi: http://dx.doi.org/10.1002/mds.10603.

96. Quagliato LB, Viana MA, Quagliato EM, Simins S. Olfaction and essential tremor. *Arq Neuropsiquiatr* 2009;67:21–24, doi: http://dx.doi.org/10.1590/S0004-282X2009000100006.

97. Benito-León J, Bermejo-Pareja F, Vega S, Louis ED. Total daily sleep duration and the risk of dementia: A prospective population-based study. *Eur J Neurol* 2009;16:990–997.

98. Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson’s disease. *J Parkinsons Dis* 2014;4:211–221, doi: 10.3233/JPD-130301.

99. Adler CH, Hentz JG, Shill HA, et al. Probable RBD is increased in Parkinson’s disease but not in essential tremor or restless legs syndrome. *Parkinsonism Relat Disord* 2011;17:456–458, doi: http://dx.doi.org/10.1016/j.parkreldis.2011.05.007.

100. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Lorenzo-Betancor O, Pastor P, Agundez JA. Update on genetics of essential tremor. *Acta Neurol Stand* 2013;128:359–371, doi: http://dx.doi.org/10.1111/ane.12148.

101. Louis ED, Levy G, Mejia-Santana H, et al. Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. *Neurology* 2003;61:931–936, doi: http://dx.doi.org/10.1212/WNL.61.7.931.
Is Essential Tremor a Neurodegenerative Disease? Benito-León J

102. Rocca WA, Bower JH, Ahlskog JE, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson’s disease. *Mov Disord* 2007;22:1607–1614, doi: http://dx.doi.org/10.1002/mds.21584.

103. Louis ED, Borden S, Moskowitz CB. Essential tremor centralized brain repository: Diagnostic validity and clinical characteristics of a highly selected group of essential tremor cases. *Mov Disord* 2005;20:1361–1365, doi: http://dx.doi.org/10.1002/mds.20583.

104. Louis ED, Vonsattel JP, Honig LS, Ross GW, Lyons KE, Pahwa R. Neuropathologic findings in essential tremor. *Neurology* 2006;66:1756–1759, doi: http://dx.doi.org/10.1212/01.wnl.0000218162.80315.b9.

105. Matsumoto R, Nakano I, Arai N, Oda M, Yagishita S, Hashizume Y. Loss of the dentate nucleus neurons is associated with torpdo formation: A morphometric study in progressive supranuclear palsy and dentatorubropallidolysian atrophy. *Acta Neuropathol* 1998;95:149–155, doi: http://dx.doi.org/10.1007/s004010050779.

106. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. *Brain* 2002;125:1760–1771, doi: http://dx.doi.org/10.1093/brain/awf184.

107. Axedor JF, Louis ED, Honig LS, et al. Reduced Purkinje cell number in essential tremor: A postmortem study. *Arch Neurol* 2008;65:101–107, doi: http://dx.doi.org/10.1001/archneur.2007.8.

108. Louis ED, Faust PL, Ma KJ, Yu M, Cortes E, Vonsattel JP. Torpedoes in the cerebellar vermis in essential tremor cases vs. controls. *Cerebellum* 2011;10:812–819, doi: http://dx.doi.org/10.1007/s12311-011-0291-0.

109. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain* 2007;130:3297–3307, doi: http://dx.doi.org/10.1093/brain/awm266.

110. Erickson-Davis CR, Faust PL, Vonsattel JP, Gupta S, Honig LS, Louis ED. “Hairy baskets” associated with degenerative palsy and degenerative cerebellar cell changes in essential tremor. *J Neuropathol Exp Neurol* 2010;69:262–271, doi: http://dx.doi.org/10.1097/NEN.0b013e3181d1ad04.

111. Symanski C, Shill HA, Dugger B, et al. Essential tremor is not associated with cerebellar Purkinje cell loss. *Mov Disord* 2014;29:496–500, doi: http://dx.doi.org/10.1002/mds.25845.

112. Rajput AH, Robinson CA, Rajput ML, Rajput A. Cerebellar Purkinje cell loss is not pathognomonic of essential tremor. *Parkinsonism Relat Disord* 2011;17:16–21, doi: http://dx.doi.org/10.1016/j.parkreldis.2010.08.009.

113. Louis ED, Lee M, Cortes E, Vonsattel JP, Faust PL. Matching asymmetry of tremor with asymmetry of postmortem cerebellar hemispheric changes in essential Tremor. *Cerebellum* 2014;13:462–470, doi: 10.1007/s12311-014-0560-9.

114. Buecher SF, Seclos KC, Dodel RC, Reiser M, Oertel WH. Activation mapping in essential tremor with functional magnetic resonance imaging. *Ann Neurol* 1997;41:32–40, doi: http://dx.doi.org/10.1002/ana.410410180.

115. Colebatch JG, Findley LJ, Frackowiak RS, Marsden CD, Brooks DJ. Preliminary report: Activation of the cerebellum in essential tremor. *Lancet* 1990;336:1028–1030, doi: http://dx.doi.org/10.1016/0140-6736(90)92489-5.

116. Jenkins IH, Bain PG, Colebatch JG, et al. A positron emission tomography study of essential tremor: Evidence for overactivity of cerebellar connections. *Ann Neurol* 1993;34:82–90, doi: http://dx.doi.org/10.1002/ana.410340115.

117. Louis ED, Shungu DC, Mao X, Chan S, Jurewicz EC. Cerebellar metabolic symmetry in essential tremor studied with 1H magnetic resonance spectroscopic imaging: Implications for disease pathology. *Mov Disord* 2004;19:672–677, doi: http://dx.doi.org/10.1002/mds.20019.

118. Pagan FL, Butman JA, Dambrosia JM, Hallet M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. *Neurology* 2003;60:1344–1347, doi: http://dx.doi.org/10.1212/01.WNL.0000063885.15873.0D.

119. Louis ED, Shungu DC, Chan S, Mao X, Jurewicz EC, Watner D. Metabolic abnormality in the cerebellum in patients with essential tremor: A proton magnetic resonance spectroscopic imaging study. *Neurosci Lett* 2002;333:17–20, doi: http://dx.doi.org/10.1016/S0304-3940(02)00966-7.

120. Klein JC, Lorenz B, Kang JS, et al. Diffusion tensor imaging of white matter involvement in essential tremor. *Hum Brain Mapp* 2011;32:996–904, doi: http://dx.doi.org/10.1002/hbm.21077.

121. Nicoletti G, Manners D, Novellino F, et al. Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. *Neurology* 2010;74:983–994, doi: http://dx.doi.org/10.1212/WNL.0b013e3181d5a460.

122. Shin DH, Han BS, Kim HS, Lee PH. Diffusion tensor imaging in patients with essential tremor. *AJNR Am J Neuroradiol* 2008;29:1692–1697, doi: http://dx.doi.org/10.1097/ajnr.A1190.

123. Quattrone A, Cerasa A, Messina D, et al. Essential head tremor is associated with cerebellar vermis atrophy: A volumetric and voxel-based morphometry MR imaging study. *AJNR Am J Neuroradiol* 2008;29:1692–1697, doi: http://dx.doi.org/10.1097/ajnr.A1544.

124. Daniels C, Peller M, Wolf S, et al. Voxel-based morphometry shows no decreases in cerebellar gray matter volume in essential tremor. *Neurology* 2006;67:1452–1456, doi: http://dx.doi.org/10.1212/01.wnl.0000240130.94408.99.

125. Cerasa A, Messina D, Nicoletti G, et al. Cerebellar atrophy in essential tremor using an automated segmentation method. *AJNR Am J Neuroradiol* 2009;30:1240–1243, doi: http://dx.doi.org/10.3174/ajnr.A1544.

126. Passamonti L, Cerasa A, Quattrone A. Neuroimaging of essential tremor: What is the evidence for cerebellar involvement? *Tremor Other Hyperkinet Mov* 2012;2: http://tremorjournal.org/article/view/67.

127. Basgepally BS, Bhatt MD, Chandran V, et al. Decrease in cerebral and cerebellar gray matter in essential tremor: A voxel-based morphometric analysis under 3T MRI. *J Neuromaging* 2012;22:275–278, doi: http://dx.doi.org/10.1111/j.1552-6569.2011.00598.x.

128. Kurtis MM. Essential tremor: Is it a neurodegenerative disease? No. *J Neural Transm* 2012;119:1375–1381; discussion 1373, doi: http://dx.doi.org/10.1007/s00702-012-0875-y.

129. Bermejo-Pareja F, Benito-León J. [Essential tremor is a neurodegenerative disease]. *Med Clin (Barc)* 2010;135:626–627; author reply 627, doi: http://dx.doi.org/10.1016/j.medcli.2009.09.043.

130. Bonuccelli U. Essential tremor is a neurodegenerative disease. *J Neural Transm* 2012;119:1383–1387; discussion 1373, doi: http://dx.doi.org/10.1007/s00702-012-0878-8.